The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Insulatard insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Mixtard insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Monotard insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Protaphane insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Ultratard insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Velosulin insulin human (rDNA) | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2002-10-07 | Order → |
| Inductos dibotermin alfa | Medtronic BioPharma B.V. | Tibial Fractures; Fracture Fixation, Internal; Spinal Fusion | 🇪🇺 EU 2002-09-09 | Order → |
| Ambirix hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Hepatitis A; Immunization | 🇪🇺 EU 2002-08-30 | Order → |
| Evra norelgestromin;ethinyl estradiol | Gedeon Richter Plc. | Contraception | 🇪🇺 EU 2002-08-22 | Order → |
| Neulasta pegfilgrastim | Amgen Europe B.V. | Cancer; Neutropenia; Febrile Neutropenia; Chemotherapy-Induced Febrile Neutropenia | 🇪🇺 EU 2002-08-22 | Order → |
| Neupopeg pegfilgrastim | Dompé Biotec S.p.A. | Cancer | 🇪🇺 EU 2002-08-22 | Order → |
| Xigris drotrecogin alfa (activated) Exceptional circumstances | Eli Lilly Nederland B.V. | Sepsis; Multiple Organ Failure | 🇪🇺 EU 2002-08-22 | Order → |
| Pegasys peginterferon alfa-2a | pharmaand GmbH | Hepatitis C, Chronic; Hepatitis B, Chronic; Polycythemia Vera; Thrombocythemia, Essential | 🇪🇺 EU 2002-06-20 | Order → |
| Tamiflu oseltamivir | Roche Registration GmbH | Influenza, Human | 🇪🇺 EU 2002-06-20 | Order → |
| Axura memantine | Merz Pharmaceuticals GmbH | Alzheimer Disease | 🇪🇺 EU 2002-05-17 | Order → |
| Opatanol olopatadine | Novartis Europharm Limited | Conjunctivitis, Allergic | 🇪🇺 EU 2002-05-16 | Order → |
| Ebixa memantine | H. Lundbeck A/S | Alzheimer Disease | 🇪🇺 EU 2002-05-15 | Order → |
| Tracleer bosentan | Scleroderma, Systemic; Hypertension, Pulmonary | 🇪🇺 EU 2002-05-14 | Order → | |
| PritorPlus telmisartan;hydrochlorothiazide | Bayer AG | Hypertension | 🇪🇺 EU 2002-04-22 | Order → |
| Kinzalkomb telmisartan;hydrochlorothiazide | Bayer AG | Hypertension | 🇪🇺 EU 2002-04-19 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.